Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 26;62(5):e02423-17.
doi: 10.1128/AAC.02423-17. Print 2018 May.

In Vitro Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators against Dermatophyte Isolates

Ali Rezaei-Matehkolaei  1 , Sadegh Khodavaisy  2 , Mohamad Mahdi Alshahni  3   4 , Takashi Tamura  3   4 , Kazuo Satoh  3   4 , Mahdi Abastabar  5 , Gholam Reza Shokoohi  6 , Bahram Ahmadi  7 , Mohammad Kord  2 , Simin Taghipour  1 , Koichi Makimura  3   4 , Hamid Badali  8   9
Affiliations

In Vitro Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators against Dermatophyte Isolates

Ali Rezaei-Matehkolaei et al. Antimicrob Agents Chemother. .

Abstract

The objective of this study was to assess the in vitro activity of the novel triazole antifungal drug, efinaconazole, and five comparators (luliconazole, lanoconazole, terbinafine, itraconazole, and fluconazole) against a large collection of Trichophyton interdigitale and Trichophyton rubrum clinical isolates. The geometric mean MICs were the lowest for luliconazole (0.0005 μg/ml), followed by lanoconazole (0.002 μg/ml), efinaconazole (0.007 μg/ml), terbinafine (0.011 μg/ml), itraconazole (0.095 μg/ml), and fluconazole (12.77 μg/ml). It appears that efinaconazole, lanoconazole, and luliconazole are promising candidates for the treatment of dermatophytosis due to T. interdigitale and T. rubrum.

Keywords: dermatophytes; efinaconazole; in vitro susceptibility testing.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. de Hoog GS, Dukik K, Monod M, Packeu A, Stubbe D, Hendrickx M, Kupsch C, Stielow JB, Freeke J, Göker M, Rezaei-Matehkolaei A, Mirhendi H, Gräser Y. 2017. Toward a novel multilocus phylogenetic taxonomy for the dermatophytes. Mycopathologia 182:5–31. doi: 10.1007/s11046-016-0073-9. - DOI - PMC - PubMed
    1. Richardson MD, Warnock DW. 2012. Fungal infection: diagnosis and management, 4th ed Wiley-Blackwell, Oxford, UK.
    1. Seebacher C, Bouchara JP, Mignon B. 2008. Updates on the epidemiology of dermatophyte infections. Mycopathologia 166:335–352. doi: 10.1007/s11046-008-9100-9. - DOI - PubMed
    1. Del Rosso JQ. 2014. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol 7:10–18. - PMC - PubMed
    1. Tamura T, Asahara M, Yamamoto M, Yamaura M, Matsumura M, Goto K, Rezaei-Matehkolaei A, Mirhendi H, Makimura M, Makimura K. 2014. In vitro susceptibility of dermatomycoses agents to six antifungal drugs and evaluation by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dermatophytes. Microbiol Immunol 58:1–8. doi: 10.1111/1348-0421.12109. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources